Browsing: Novo

Novo Nordisk said Eli Lilly’s ads uses outdated research and leave out important information, which could mislead consumers

Novo Nordisk sued competitor Eli Lilly on Tuesday, alleging the drugmaker engaged in false advertising by claiming its GLP-1 drugs are superior to Novo’s

Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly’s advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo’s latest higher-dose Wegovy and Ozempic treatments. Novo is seeking to halt the advertising, require corrective marketing, and recover damages as the companies compete in the growing obesity…

Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne

The lawsuit, filed in the U.S. District Court for the District of New Jersey, accuses the competitor of violating both state and federal false advertising and unfair competition laws

The battle of big pharma rages on as Novo Nordisk takes a shot at rival Eli Lilly in a new misleading advertising lawsuit

The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action accusing its arch rival Eli Lilly of false advertising in suggesting its weight-loss drugs perform better

Novo Nordisk A/S sued Eli Lilly & Co., accusing its rival of misleading advertising as competition in the U.S. market for obesity drugs ratchets up further

The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action accusing its arch rival Eli Lilly of false advertising in suggesting its weight-loss drugs perform better

Novo Nordisk on Tuesday filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy relative to the Danish drugmaker’s rival injections.